Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices.

Zemanick E, Burgel PR, Taccetti G, Holmes A, Ratjen F, Byrnes CA, Waters VJ, Bell SC, VanDevanter DR, Stuart Elborn J, Flume PA; Antimicrobial Resistance International Working Group in Cystic Fibrosis.

J Cyst Fibros. 2019 Oct 31. pii: S1569-1993(19)30919-1. doi: 10.1016/j.jcf.2019.10.006. [Epub ahead of print]

PMID:
31680041
2.

Pulmonary Complications of Cystic Fibrosis.

Garcia B, Flume PA.

Semin Respir Crit Care Med. 2019 Oct 28. doi: 10.1055/s-0039-1697639. [Epub ahead of print]

PMID:
31659729
3.

Clinical care for cystic fibrosis: preparing for the future now.

Konstan MW, Flume PA.

Lancet Respir Med. 2019 Sep 27. pii: S2213-2600(19)30334-0. doi: 10.1016/S2213-2600(19)30334-0. [Epub ahead of print] No abstract available.

PMID:
31570320
4.

Impact of a Reduction in Susceptibility Testing for Pseudomonas aeruginosa in a Cystic Fibrosis Program.

Ponce MC, Svendsen E, Steed L, Flume PA.

Am J Respir Crit Care Med. 2019 Aug 30. doi: 10.1164/rccm.201903-0576LE. [Epub ahead of print] No abstract available.

PMID:
31469583
5.

Predictors of pulmonary exacerbation treatment in cystic fibrosis.

Sanders DB, Ostrenga JS, Rosenfeld M, Fink AK, Schechter MS, Sawicki GS, Flume PA, Morgan WJ.

J Cyst Fibros. 2019 Jun 27. pii: S1569-1993(18)30763-X. doi: 10.1016/j.jcf.2019.06.008. [Epub ahead of print]

PMID:
31257102
6.

A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.

Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G; VX15-661-113 Investigator Group.

J Cyst Fibros. 2019 Sep;18(5):708-713. doi: 10.1016/j.jcf.2019.06.009. Epub 2019 Jun 26.

7.

Rheumatoid arthritis-associated bronchiectasis - Authors' reply.

Flume PA, Chalmers JD, Olivier KN.

Lancet. 2019 May 18;393(10185):2036. doi: 10.1016/S0140-6736(19)30012-1. No abstract available.

PMID:
31106746
8.

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.

Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P; Antimicrobial Resistance International Working Group in Cystic Fibrosis .

Clin Infect Dis. 2019 Oct 30;69(10):1812-1816. doi: 10.1093/cid/ciz364.

PMID:
31056660
9.

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.

Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR; Antimicrobial Resistance in Cystic Fibrosis InternationalWorking Group.

J Cyst Fibros. 2019 Mar;18(2):236-243. doi: 10.1016/j.jcf.2019.01.008. Epub 2019 Jan 30.

PMID:
30709744
10.

The study of CFTR modulators in the very young.

Flume PA.

Lancet Respir Med. 2019 Apr;7(4):287-289. doi: 10.1016/S2213-2600(18)30503-4. Epub 2019 Jan 24. No abstract available.

PMID:
30686766
11.

JCF - progress in 2018.

Bell SC, Castellani C, Flume PA.

J Cyst Fibros. 2019 Jan;18(1):1-5. doi: 10.1016/j.jcf.2018.12.008. No abstract available.

PMID:
30665544
12.

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities.

Nichols DP, Durmowicz AG, Field A, Flume PA, VanDevanter DR, Mayer-Hamblett N.

Ann Am Thorac Soc. 2019 May;16(5):534-539. doi: 10.1513/AnnalsATS.201812-863OT. No abstract available.

13.

Providing Restricted Access to an Electronic Medical Record for Research Monitoring.

Bell L, Gentilin S, Sonne S, Mauney T, Flume P.

Clin Res (Alex). 2018;32(3). pii: 0034. Epub 2018 Mar 13.

14.

Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis.

Flume PA, Suthoff ED, Kosinski M, Marigowda G, Quittner AL.

J Cyst Fibros. 2019 Sep;18(5):737-742. doi: 10.1016/j.jcf.2018.12.004. Epub 2018 Dec 23.

15.

Antimicrobial resistance in cystic fibrosis: Does it matter?

Flume PA, Waters VJ, Bell SC, Van Devanter DR, Stuart Elborn J; Antimicrobial Resistance in Cystic Fibrosis International Working Group.

J Cyst Fibros. 2018 Nov;17(6):687-689. doi: 10.1016/j.jcf.2018.08.015. Epub 2018 Sep 27. No abstract available.

PMID:
30270113
16.

Defining antimicrobial resistance in cystic fibrosis.

Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ; Antimicrobial Resistance in Cystic Fibrosis International Working Group.

J Cyst Fibros. 2018 Nov;17(6):696-704. doi: 10.1016/j.jcf.2018.08.014. Epub 2018 Sep 25. Review.

PMID:
30266518
17.

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.

Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group.

Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.

PMID:
30216086
18.

Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.

Flume PA, Chalmers JD, Olivier KN.

Lancet. 2018 Sep 8;392(10150):880-890. doi: 10.1016/S0140-6736(18)31767-7. Review.

19.

Optimizing outcomes of pulmonary exacerbations in cystic fibrosis.

Szentpetery S, Flume PA.

Curr Opin Pulm Med. 2018 Nov;24(6):606-611. doi: 10.1097/MCP.0000000000000519. Review.

PMID:
30124523
20.

Nontuberculous Mycobacteria in Cystic Fibrosis.

Furukawa BS, Flume PA.

Semin Respir Crit Care Med. 2018 Jun;39(3):383-391. doi: 10.1055/s-0038-1651495. Epub 2018 Aug 2. Review.

PMID:
30071553
21.

Mycobacterial Disease: Evolving Concepts.

Flume PA, Winthrop KL.

Semin Respir Crit Care Med. 2018 Jun;39(3):269. doi: 10.1055/s-0038-1660862. Epub 2018 Aug 2. No abstract available.

PMID:
30071542
22.

In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates.

Forrester JB, Steed LL, Santevecchi BA, Flume P, Palmer-Long GE, Bosso JA.

Open Forum Infect Dis. 2018 Jul 2;5(7):ofy158. doi: 10.1093/ofid/ofy158. eCollection 2018 Jul.

23.

Benefits of set length antibiotic treatment for pulmonary exacerbations.

Goss CH, Somayaji R, Flume PA.

Lancet Respir Med. 2018 Aug;6(8):575-577. doi: 10.1016/S2213-2600(18)30267-4. Epub 2018 Jun 27. No abstract available.

24.

"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Gilligan PH, Downey DG, Elborn JS, Flume PA, Funk S, Gilpin D, Kidd TJ, McCaughan J, Millar BC, Murphy PG, Rendall JC, Tunney MM, Moore JE.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00193-18. doi: 10.1128/JCM.00193-18. Print 2018 Sep.

25.

Unmet needs in cystic fibrosis: the next steps in improving outcomes.

West NE, Flume PA.

Expert Rev Respir Med. 2018 Jul;12(7):585-593. doi: 10.1080/17476348.2018.1483723. Epub 2018 Jun 19. Review.

26.

Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.

Jennings MT, Flume PA.

Ann Am Thorac Soc. 2018 Aug;15(8):897-902. doi: 10.1513/AnnalsATS.201802-075FR.

27.

ECFS best practice guidelines: the 2018 revision.

Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P.

J Cyst Fibros. 2018 Mar;17(2):153-178. doi: 10.1016/j.jcf.2018.02.006. Epub 2018 Mar 3. Review.

28.

Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis.

Brown KL, Flume PA.

J Genet Couns. 2018 Sep;27(5):1049-1054. doi: 10.1007/s10897-018-0220-1. Epub 2018 Feb 10.

PMID:
29429040
29.

Response to Commentary: Regulatory Support Improves Subsequent IRB Approval Rates in Studies Initially Deemed Not Ready for Review-A CTSA Institution's Experience.

Sonne S, Gentilin S, Sampson RR, Bell L, Mauney T, Young S, Bright K, Flume P.

J Empir Res Hum Res Ethics. 2018 Apr;13(2):148. doi: 10.1177/1556264617753316. Epub 2018 Jan 18. No abstract available.

PMID:
29345186
30.

Regulatory Support Improves Subsequent IRB Approval Rates in Studies Initially Deemed Not Ready for Review: A CTSA Institution's Experience.

Sonne S, Gentilin S, Sampson RR, Bell L, Mauney T, Young S, Bright K, Flume P.

J Empir Res Hum Res Ethics. 2018 Apr;13(2):139-144. doi: 10.1177/1556264617752725. Epub 2018 Jan 18.

31.

Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.

Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH; STOP Study Group.

Contemp Clin Trials. 2018 Jan;64:35-40. doi: 10.1016/j.cct.2017.11.012. Epub 2017 Nov 21.

32.

Learning's from the Editors Desk - 2017.

Bell SC, Castellani C, Flume PA.

J Cyst Fibros. 2017 Nov;16(6):645-646. doi: 10.1016/j.jcf.2017.10.001. No abstract available.

33.

Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.

Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS.

J Cyst Fibros. 2018 Jan;17(1):83-88. doi: 10.1016/j.jcf.2017.06.002. Epub 2017 Jun 24.

34.

Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.

Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O'Donnell A, Aksamit T; EMBARC/BRR definitions working group.

Eur Respir J. 2017 Jun 8;49(6). pii: 1700051. doi: 10.1183/13993003.00051-2017. Print 2017 Jun.

35.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.

36.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators.

J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.

37.

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.

VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):607-615. doi: 10.1016/j.jcf.2017.04.004. Epub 2017 Apr 21.

38.

The Cystic Fibrosis Survival Gap: Why Do Canadians Fare Better Than Americans?

Flume PA, VanDevanter DR.

Ann Intern Med. 2017 Apr 18;166(8):599-600. doi: 10.7326/M17-0564. Epub 2017 Mar 14. No abstract available.

PMID:
28289748
39.

Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.

Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL.

J Cyst Fibros. 2017 May;16(3):371-379. doi: 10.1016/j.jcf.2017.01.009. Epub 2017 Feb 13.

40.

The challenges of maintaining momentum in CF drug development and approval - Commentary.

Flume PA, VanDevanter DR.

J Cyst Fibros. 2017 Mar;16(2):170-171. doi: 10.1016/j.jcf.2017.01.014. Epub 2017 Feb 5. No abstract available.

41.

Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough?

Bell SC, Flume PA.

Thorax. 2017 Apr;72(4):297-299. doi: 10.1136/thoraxjnl-2016-209605. Epub 2017 Jan 11. No abstract available.

PMID:
28077615
42.

Current strategies for the long-term assessment, monitoring, and management of cystic fibrosis patients treated with CFTR modulator therapy.

Elborn JS, Davies J, Mall MA, Flume PA, Plant B.

J Cyst Fibros. 2017 Jan;16(1):163-164. doi: 10.1016/j.jcf.2016.11.009. Epub 2016 Dec 13.

43.

Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.

Olivier KN, Griffith DE, Eagle G, McGinnis JP 2nd, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume PA, Dorgan D, Salathe M, Brown-Elliott BA, Gupta R, Wallace RJ Jr.

Am J Respir Crit Care Med. 2017 Mar 15;195(6):814-823. doi: 10.1164/rccm.201604-0700OC.

44.

Bronchodilators in cystic fibrosis: a critical analysis.

Barry PJ, Flume PA.

Expert Rev Respir Med. 2017 Jan;11(1):13-20. doi: 10.1080/17476348.2017.1246358. Epub 2016 Oct 27. Review.

PMID:
27718752
45.

Efficacy measures for clinical trials: A review series.

Flume PA, VanDevanter DR.

J Cyst Fibros. 2016 Jul;15(4):415. doi: 10.1016/j.jcf.2016.06.002. Epub 2016 Jun 15. No abstract available.

46.

Adults with cystic fibrosis in Portugal: A first step towards improvement.

Raja TH, Flume PA.

Rev Port Pneumol (2006). 2016 May-Jun;22(3):139-40. doi: 10.1016/j.rppnen.2016.05.001. No abstract available.

47.

Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.

Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, Lewis SA, Ramsey BW.

J Cyst Fibros. 2016 Nov;15(6):809-815. doi: 10.1016/j.jcf.2016.05.001. Epub 2016 May 24.

48.

Corrigendum to "Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study" [J Cyst Fibros (2015) 632-638].

Thompson V, Mayer-Hamblett N, Kloster M, Bilton D, Flume PA.

J Cyst Fibros. 2016 Sep;15(5):e54-e55. doi: 10.1016/j.jcf.2016.04.010. Epub 2016 May 17. No abstract available.

49.

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

VanDevanter DR, Flume PA, Morris N, Konstan MW.

J Cyst Fibros. 2016 Nov;15(6):783-790. doi: 10.1016/j.jcf.2016.04.005. Epub 2016 Apr 29.

50.

Supplemental Content

Support Center